Skin Response to Mogamulizumab in Patients With Mycosis Fungoides and Sezary Syndrome: A Retrospective, Real World Cohort
- 19 August 2025
- journal article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (12) , e1098-e1107.e3
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- NIH National Cancer Institute (P30 CA008748)
This publication has 16 references indexed in Scilit:
- Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndromeJournal of the European Academy of Dermatology and Venereology, 2022
- Efficacy of mogamulizumab in mycosis fungoides by patient blood involvement and time to response analysis in mycosis fungoides and Sézary syndrome: a post hoc analysis of the MAVORIC studyEuropean Journal of Cancer, 2021
- Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trialJournal of the European Academy of Dermatology and Venereology, 2021
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trialThe Lancet Oncology, 2018
- Cutaneous T-cell LymphomaClinics In Laboratory Medicine, 2017
- Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30‐positive Hodgkin's lymphoma or systemic anaplastic large‐cell lymphomaCancer Science, 2014
- Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humansProceedings of the National Academy of Sciences, 2013
- Chemokine Receptor Expression in Cutaneous T cell and NK/T-cell Lymphomas: Immunohistochemical Staining and In Vitro Chemotactic AssayAmerican Journal of Surgical Pathology, 2006
- Chemokine Receptor Expression on Neoplastic and Reactive T Cells in the Skin at Different Stages of Mycosis FungoidesJournal of Investigative Dermatology, 2003
- Increased CCR4 Expression in Cutaneous T Cell LymphomaJournal of Investigative Dermatology, 2002